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Abstract
Background: p53 is recognized as a critical regulator of the cell cycle and apoptosis. Mounting
evidence also suggests a role for p53 in differentiation of cells including neuronal precursors. We
studied the transcriptional role of p53 during nerve growth factor-induced differentiation of the
PC12 line into neuron-like cells. We hypothesized that p53 contributed to PC12 differentiation
through the regulation of gene targets distinct from its known transcriptional targets for apoptosis
or DNA repair.
Results: Using a genome-wide chromatin immunoprecipitation cloning technique, we identified
and validated 14 novel p53-regulated genes following NGF treatment. The data show p53 protein
was transcriptionally activated and contributed to NGF-mediated neurite outgrowth during
differentiation of PC12 cells. Furthermore, we describe stimulus-specific regulation of a subset of
these target genes by p53. The most salient differentiation-relevant target genes included wnt7b
involved in dendritic extension and the tfcp2l4/grhl3 grainyhead homolog implicated in ectodermal
development. Additional targets included brk, sdk2, sesn3, txnl2, dusp5, pon3, lect1, pkcbpb15 and
other genes.
Conclusion: Within the PC12 neuronal context, putative p53-occupied genomic loci spanned the
entire Rattus norvegicus genome upon NGF treatment. We conclude that receptor-mediated p53
transcriptional activity is involved in PC12 differentiation and may suggest a contributory role for
p53 in neuronal development.
Background
The tumor suppressor p53 is recognized as a critical regu-
lator of cell cycle progression and apoptosis, incorporat-
ing signals from DNA damage and other cellular stressors
to decide cell fate [1]. Disruption of p53 activity through
direct mutation or regulatory dysfunction is a demon-
strated causal factor in a large proportion of human malig-
nancies [2]. As a transcription factor, many of the
functional cellular roles of the p53 protein are elicited
through direct DNA binding to sequence-specific cis-regu-
latory elements [3] leading to the transactivation or tran-
srepression of target genes. Many of these target genes
have been described through both computational and
biochemical methods [4-7].
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Evidence suggests a functional role for p53 in differentia-
tion and development, particularly within the nervous
system. While initial p53-null mouse models were
described as phenotypically normal at birth with mark-
edly increased tumor development later in life [8,9], later
studies demonstrated a proportion of p53-/- mice had
defects in neural tube closure resulting in exencephaly
[10,11].  In vivo measurements in p53-responsive lacZ
transgenic mice demonstrated elevated p53 transcrip-
tional activity in the embryonic and early gestational nerv-
ous system [12], while high levels of p53 expression have
been described throughout the chick, rat, mouse and
Xenopus embryo [13-17] through midgestation. p53 func-
tional activity has been further implicated in the differen-
tiation of neuronal precursors [10,11,16] and is
transcriptionally active within the nucleus of differentiat-
ing primary hippocampal neurons and oligodendrocytes
[18], while p53 is inactive and localized to the cytoplasm
of postmitotic differentiated sympathetic neurons [19].
p53 transcriptional activity may be further involved in the
differentiation of other non-neuronal cell types. Tran-
scriptional activity of p53 plays a direct role in embryonic
stem cell differentiation by suppression of the Nanog gene
[20], and can directly induce Xenopus  homebox gene
expression [21]. Involvement of p53 has also been shown
in spermatogenesis [22], eye development [23] renal
development [24], osteogenesis [25], immune develop-
ment [26], lung development [27] and muscle differenti-
ation [28]. Despite data supporting the transcriptional
activity of p53 protein in differentiation, few genetic tar-
gets have been described and fewer still within a neuronal
context.
Discovery of non-genotoxic mechanisms through which
p53 protein may be activated within tumor cells harbor-
ing wild-type p53 remains an important therapeutic
objective, both in effort to alleviate traditional off-target
chemotherapeutic side-effects and to prevent the unpre-
dictable mutagenicity characteristic of these therapies.
Wild-type p53 can be activated in several malignancies by
treatment with nerve growth factor [29] or pharmacologic
agents [30-33], occurring through mechanisms sparing
cells from the concomitant genotoxicity following chem-
otherapy. Recent evidence demonstrates that while p53
transcriptional regulation of target genes may be stimulus-
dependent (e.g. DNA damage), promoter occupancy is
generalized and may occur independently of the activat-
ing genotoxic stimulus [34]. Whether this paradigm is
also applicable to nongenotoxic p53 stimuli compared to
DNA damage-induced p53 activation is unclear. NGF-
mediated p53 activation mainly results in decreased pro-
liferative ability of tumor cells and not apoptosis [29],
raising the question of whether NGF-regulated p53 activ-
ity is distinguishable from other means of p53 activation
like DNA damage. While the mechanism of NGF-induced
p53 activation is uncertain, inquiry into the transcrip-
tional program following such activation is warranted to
discern possible receptor-dependent p53 transactivational
selectivity compared to genotoxic agents.
In the current study, the p53 transcriptional program was
studied during nerve growth factor-induced differentia-
tion of ectoderm-derived rat PC12 pheochromocytoma
cells. A global chromatin immunoprecipitation-based
screen was used to identify genetic elements bound to and
regulated by p53. Treatment of PC12 cells with NGF
induces differentiation into neuron-like cells marked by
cell cycle arrest and neurite extension [35] along with
marked changes in gene expression [36] and signaling
pathway activity [37]. NGF-responsive p53 activity [38]
has a functional contribution towards NGF-mediated
PC12 differentiation [39-41], but a role in gene-specific
transactivation has not yet been established. We hypothe-
sized that marked accumulation of p53 protein within dif-
ferentiating PC12 cells would be accompanied by
concomitant transcriptional regulation of genes involved
in differentiation and cell cycle arrest. Furthermore, we
hypothesized that genomic elements regulated by p53
during neuronal differentiation may be unique from
those regulated during genotoxic stress and apoptosis. We
now report that p53 protein is transcriptionally activated
in NGF-mediated neuronal differentiation and describe
its binding to a number of novel and previously unre-
ported genomic regions as well as the transcriptional out-
come of this binding. We identify and validate genomic
targets of p53 activity within the differentiating neuron-
like cell, and demonstrate selectivity between NGF-acti-
vated versus genotoxicant-activated p53 transcriptional
activity in a select number of p53 target genes.
Results
NGF induces activation of p53 protein within PC12 cells
PC12 morphologic changes and neurite extension consist-
ent with differentiation were visible within 12 hours of
NGF addition to the media and became marked over the
course of 7 days [See Additional file 1; Figure 1A]. NGF-
dependent differentiation after 7 days treatment in PC12
cells was evidenced by expression of the dopamine trans-
porter, a marker for dopamine generation [42] and trans-
port, and decreased nestin immunoreactivity, indicating
loss of undifferentiated phenotype [43] [See Additional
file 1; Figure 1B]. In agreement with previous reports [44],
cell cycle analysis by flow cytometry using FITC-BrdU
labeling of total and newly synthesized DNA, respectively,
revealed the population of cells within S phase was
decreased to ~1% of the total cell population within 96
hours of NGF treatment [See Additional file 1; Figure 2A].
Reduction of S phase cells was accompanied by a concom-
itant increase in the number of cells within G1 phase after
7 days of NGF exposure [See Additional file 1; Figure 2B].BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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Analysis of p53 knockdown PC12 cell lines Figure 2
Analysis of p53 knockdown PC12 cell lines. A) RT-PCR and immu-
noblot depicting levels of p53 mRNA and protein in wild-type 
naïve PC12 cells compared to 7-day NGF (50 ng/mL) differenti-
ated wild-type and anti-p53 shRNA expressing PC12 cells. 
GAPDH mRNA levels serve as loading control for RT-PCR, while 
actin serves as immunoblot loading control. p53 and GAPDH 
mRNA levels in each sample were quantitated using ImageJ and 
normalized to naïve RNA levels, depicted under each band. PCR 
cycle number used is shown on right of gel image. p53 RNA and 
protein levels (and knockdown efficiency) were lowest in 
p53#3low cells, followed by p53#2mid and p53#4mid cell lines. B) 
Representative image of wild-type and p53#3low PC12 cells fol-
lowing 3 days treatment with 50 ng/mL NGF.
PC12 neuronal differentiation involves p53 stabilization and  activation Figure 1
PC12 neuronal differentiation involves p53 stabilization and 
activation. A) Immunoblot depicting total and phospho-serine 
15 p53 protein levels over time following 50 ng/mL NGF 
2.5S, with total actin protein levels serving as loading control. 
B) RT-PCR levels of p53 mRNA over time following NGF 
2.5S treatment compared to β-actin loading control. C) Luci-
ferase activity in PC12 cells transfected with p53TAluc 
reporter vector following NGF 2.5S treatment at indicated 
time intervals, where p ≤ 0.05. Error bars represent standard 
deviation.BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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p53 protein levels were significantly elevated in response
to NGF treatment in PC12 cells as previously described by
others [44,45]. Accumulation of p53 protein was detecta-
ble at 8 hours following NGF exposure and remained
highly elevated over the course of 7 days (Figure 1A).
Phosphorylation of p53 protein at serine 15, which is typ-
ically needed for transactivation, began at about 8 hours
after NGF treatment and remained highly phosphorylated
throughout 7 days (Figure 1A). Accumulation of p53 pro-
tein can be attributed to protein stabilization since levels
of p53 mRNA remained unchanged over a 7-day course of
NGF treatment (Figure 1B). Virtually all p53 protein was
localized within the nucleus in 7 day NGF-differentiated
cells, as determined by immunoblot of nuclear and cyto-
plasmic fractions (data not shown). Accumulated p53
protein was transcriptionally active, as demonstrated by
luciferase expression using the p53TA-luc reporter vector
in differentiated compared to naïve cells (Figure 1C).
The role of p53 activity in differentiation of NGF treated
PC12 cells was investigated in anti-p53 shRNA-expressing
PC12 cells (Figure 2A). Three stable PC12 lines expressing
different anti-p53 shRNAs were created to observe p53-
dependent function in PC12 differentiation. p53 RNA
silencing resulted in reduced p53 protein levels, with
p53#3low having the lowest levels, followed by
p53#2mid and p53#4mid. The p53#4mid cell line repro-
ducibly expressed p53 protein levels approaching those
observed in the wild-type cell. In combination, these three
shRNA cell lines formed a gradient of p53 protein expres-
sion compared to the wild-type cell. While no apparent
morphological differences were noted in the shRNA
expressing cell lines maintained in the naïve state, NGF
differentiation of these cells demonstrated reduced early
neurite extension compared to their wild-type counter-
parts. Within 3 days of NGF exposure, p53#3low cells had
markedly reduced neurite outgrowth compared to wild-
type cells (Figure 2B), lasting up to 7 days (data not
shown). These results agree with prior work showing dis-
ruption of morphological differentiation following both
dominant-negative and temperature-sensitive p53 trans-
fection into PC12 cells [18,39,46].
Chromatin immunoprecipitation and cloning of ChIP-
generated tags
p53 DNA binding was studied in seven-day differentiated
PC12 cells via chromatin immunoprecipitation (ChIP)
analysis. Preliminary assay validation demonstrated p53
binding to a known, well-defined binding site within the
p21Waf1/Cip1 promoter at a 2-fold greater level in differenti-
ated versus naïve cells [See Additional file 1; Figure 3].
Greater than 10-fold increased p53 occupancy at the
p21Waf1/Cip1 proximal binding site was detected with FL-
393 immunoprecipitating antibody compared to IgG
alone, confirming antibody specificity [See Additional file
1; Figure 3]. Having validated p53 occupancy to a known
gene promoter, ChIP-enriched DNA from differentiated
PC12 cells was amplified, concatemerized and cloned.
Cloned concatemers were sequenced and separated,
resulting in 7,184 individual DNA tags representative of
putative p53-occupied locations within the PC12 genome
[See Additional file 1; Table 1]. Tags were aligned to the
Rattus norvegicus genome and locations with >1 tag map-
ping within a 2 kb area ("clusters") were identified. Clus-
ter chromosomal coordinates and sequences have been
compiled and organized [see Additional File 2]. Sequence
data were obtained for 500 bp upstream and downstream
of each tag, single or clustered, and tags were recompiled
to represent the original p53-bound ChIP-enriched frag-
ments. Since the number of sequenced tags were non-sat-
urating compared to the total population of p53-occupied
fragments, both clusters and single tags were potentially
informative. Tags representing putative p53-occupied
genomic fragments were found to span the entire Rattus
norvegicus  genome in addition to known p53 binding
regions within the MDM2, cyclin G1 and other known tar-
get promoters, validating this experimental approach for
the study of other novel putative targets.
Recompiled tag sequences were analyzed for predicted
p53 binding sites using the p53MH algorithm [47] and
sorted according to both binding site score and location
relative to nearby genetic elements. Stringency for p53
binding site probability score was set at a cutoff of 90 (out
of 100) as determined by the p53MH algorithm using
likelihood ratio scoring and a 14 base gap size limit
between half sites. Results using these criteria demon-
strated 364 p53 binding sites within tag sequences located
in upstream 5', downstream 3' and intergenic gene
regions. Of those tags with a p53MH binding site score ≥
90 (out of 100), 56% mapped to within a gene, 25% to
the upstream 5' region and 19% to the downstream 3'
region (Figure 3B). Observed p53-occupied sites in the
PC12 genome were visualized by plotting normalized tag
alignment locations relative to a hypothetical gene size of
100 kb (Figure 3C). Scored p53 binding sites clustered to
both the 5' and 3' gene regions, while intergenic binding
sites were observed throughout the entire length of the
gene.
Validation of p53 occupancy and transcriptional 
regulation
We selected a total of 100 clusters and single tags com-
bined for ChIP-based validation of p53 occupancy based
on either the presence of a putative p53 binding site as
determined by the p53MH algorithm, or tag location rel-
ative to a genomic element of interest. Since tag sequenc-
ing and identification were not performed to saturation
we considered individual tags and clusters as potentially
informative. We recognized that selection based on highBMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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p53 binding scores alone may pose a constraint on puta-
tive regulated genes because p53-mediated transrepres-
sion can occur in both the absence of a consensus binding
site [48,49] or by binding to sites sufficiently distinct from
the consensus sequence that fall below our accepted
p53MH binding site prediction level [50]. A preponder-
ance of genes whose known functions may be relevant in
neuronal differentiation also factored into our selection of
tags and clusters for validation. We selected 100 tags for
ChIP-based validation based on criteria of ontological
classification (i.e. GO terms related to development, dif-
ferentiation or morphogenesis), known function of asso-
ciated genes, or p53 binding site score in order to identify
candidate p53-regulated targets with a role in PC12 differ-
entiation. ChIP analysis demonstrated significantly ele-
vated (p ≤ 0.05) p53 occupancy in an NGF-dependent
manner for roughly 30% of the 100 studied validation tar-
gets. Those targets to which p53 binding was significantly
increased in NGF-treated cells are shown in Figures 4, 5, 6,
7, 8. As expected, reproducible binding was demonstrated
to promoters of known p53-inducible target genes shown
in Figures 4 and 5 including p21Waf1/Cip1, MDM2 and cyc-
lin G1 (Figure 4). In addition to NGF-responsive genomic
p53 binding sites, roughly 40% of targets showed signifi-
cant p53-binding independent of NGF treatment [See
Additional file 1; Table 3]. These targets were significantly
enriched in ChIP validation when compared to negative
control regions, although no NGF-responsive changes
were noted in p53 binding. Absence of NGF-dependent
53 binding to these regions precluded further analysis
since they were beyond the objectives of this study. While
these genomic locations were ChIP-enriched, cloned and
demonstrated to be enriched once more in a validation
ChIP experiment, further study will be necessary to dem-
onstrate p53-dependent transcription.
In order to determine the transcriptional outcome of p53
binding to NGF-responsive target regions described
above, RT-PCR was performed to compare mRNA levels
for indicated targets among naïve and differentiated PC12
cells (Figures 4, 5, 6, 7, 8). p53-dependence on target gene
expression was verified using three stable anti-p53
shRNA-expressing PC12 lines with varying p53 knock-
down efficiencies. Use of the three shRNA clones formed
a gradient of p53 mRNA and protein expression (Figure
2A), where p53#3low had the lowest level of expression
and p53#2mid & p53#4mid were both reproducibly
higher with a moderate level of p53 expression. Including
known targets, a total of 14 genes were p53-induced in
differentiating PC12 cells. Importantly, we discovered ten
novel, p53-inducible targets regulated in an NGF-respon-
sive manner (Figures 4 and 5), including the sesn3 and
nme1 targets recently described to be p53 regulated either
by association or indirect experimental evidence [51,52].
In addition, the dusp5 gene was an NGF-inducible p53
target, recapitulating earlier reports of this gene being
p53-regulated [53]. Further, we report four novel p53
gene targets that demonstrated a p53-dependent repres-
sion (Figure 6). These included the pkcbpb15/trib3 locus,
where transcripts of both genes were elevated in p53-
silenced cells. We also demonstrate eleven p53 occupied
regions where transcriptional changes in nearby genes
during NGF-mediated differentiation could not be accred-
ited solely to p53 activity in the study (Figures 7 and 8),
including the previously described p53 targets snk [54]
and nck2 [5]. Additionally, new p53-occupied binding
sites were identified for the MDM4 and dyrk3 genes, for
Identification of p53-occupied genomic sites Figure 3
Identification of p53-occupied genomic sites. A) Schematic of 
chromatin immunoprecipitation (anti-p53, FL-393) cloning 
strategy. See methods for more detail. B) Location of tags 
containing putative p53 binding sites relative to known genes 
within the rat genome. Binding sites scoring 90 or above out 
of 100 using the p53MH algorithm were included in this anal-
ysis. C) A hypothetical 100 kb gene map is used to show the 
relative location of 364 of experimentally determined p53 
site-containing tags that achieved scores of ≥ 90 with the 
p53MH predictive binding algorithm. Data show that p53 
site-containing tags were found in the upstream 5', down-
stream 3' and intergenic gene regions.BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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p53-dependent induction of target genes Figure 4
p53-dependent induction of target genes. Panels A-H show site-specific qPCR ChIP results on left with standard deviation, 
where significance at p ≤ 0.05 is designated by an asterisk (*). Center tile depicts gene map of predicted p53 binding site loca-
tion and the sequence relative to annotated genes, along with exon structure and direction of transcription as per NCBI 
MapViewer conventions. Right tile represents RT-PCR gel image of each mapped target gene. RT-PCR analyses were per-
formed multiple times for each target gene and gel images are representative of consistent expression levels. mRNA levels of 
each gene in wild-type naïve PC12 cells were compared to 7-day NGF (50 ng/mL) differentiated wild-type and three anti-p53 
shRNA expressing PC12 cells (p53#3low, p53#2mid, p53#4mid). ImageJ quantitation, normalized to naïve RNA levels, is 
depicted under each band, while PCR cycle number is depicted on right of gel image. GAPDH expression levels are shown in A 
and represent a typical loading control along with no-RT negative control.BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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p53-dependent induction of additional target genes Figure 5
p53-dependent induction of additional target genes. Panels A-F show site-specific qPCR ChIP results on left with standard devi-
ation, where significance at p ≤ 0.05 is designated by an asterisk (*). GAPDH controls for RT-PCR in Figure 4 also apply to gene 
expression analyses in Figure 5. Note the p53-occupied sequence in Panel F lies between genes which were both examined for 
changes in expression. Overall display and analyses are as described in Figure 4 legend.BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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which different p53 binding locations have previously
been described [5].
The majority of p53MH-predicted p53 binding sites
within regions of validated occupancy contained either no
spacer or a short spacer, in agreement with earlier data [5].
However, there are several notable exceptions to this trend
including  wnt7b,  grhl3,  shmt1  and  sesn3  binding sites,
which contain atypical spacers from 5–13 bp separating
the individual half-sites, similar to the described p53-
binding site within the siah  promoter [55]. Consensus
binding sites derived from our data are shown in Figure 9
using the WebLogo [56] sequence analysis tool. We report
little deviation from the p53 consensus sequence for
transactivation (Figure 9a) compared to repression except
for the substitution of purine for pyrimidine at site 11
(Figure 9b). This data supports the capability for p53-reg-
ulated transcriptional repression from a consensus bind-
ing site [57].
Stimulus-dependent transcriptional regulation
Experiments were conducted to determine if p53-regu-
lated genes in differentiation were unique from those fol-
lowing genotoxicity. Expression levels of NGF-dependent
p53 target genes measured after DNA-damage by bleomy-
cin and 5-fluorouracil were compared to NGF treatment
to discriminate stimulus-dependency of p53-mediated
transcription. As expected, expression levels for p21Waf1/
Cip1 and cyclin G1 were elevated following all treatments,
confirming the transcriptional activity of p53 in all groups
(Figure 10A). Increased expression levels in three of the
NGF-responsive targets, wnt7b, pkcbpb15 and lect1 (Figure
p53-repressed target genes Figure 6
p53-repressed target genes. Panels A-D show site-specific qPCR ChIP results on left with standard deviation, where signifi-
cance at p ≤ 0.05 is designated by an asterisk (*). Note the p53-occupied sequence in Panel B lies between genes which were 
both examined for changes in expression. Display and analyses are as described in Figure 4 legend.BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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Targets with NGF-dependent increase in p53 occupancy, but where p53-dependent transactivation could not be clearly deter- mined using anti-p53 shRNA expressing cell lines Figure 7
Targets with NGF-dependent increase in p53 occupancy, but where p53-dependent transactivation could not be clearly deter-
mined using anti-p53 shRNA expressing cell lines. Panels A-H show site-specific qPCR ChIP results on left with standard devia-
tion, where significance at p ≤ 0.05 is designated by an asterisk (*). Note the p53-occupied sequences in Panels B, D and E lie 
between two genes so that were both examined for changes in expression. Display and analyses are as described in Figure 4 
legend.BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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10B) were not recapitulated in 5-FU and bleomycin
treated cells. Results demonstrate an opposite transcrip-
tional regulation for these p53-regulated targets depend-
ing upon the treatment stimulus. Although the absolute
levels varied, expression levels and direction of the
remaining p53-regulated target genes were similar regard-
less of the treatment (Figure 10C). Expression levels of all
gene targets were similar to those found earlier using RT-
PCR, with absolute differences attributed mainly to differ-
ential assay sensitivities. These data demonstrate that the
gene expression at chosen time points for some, but not
all, p53 target genes is NGF-dependent. The remaining
target genes studied, however, were induced or repressed
both by NGF receptor-mediated or genotoxic p53-induc-
ing stimuli.
Discussion
The p53 tumor suppressor is widely appreciated as a cen-
tral node in the regulation of proliferation and apoptosis
in response to various genotoxic insults. Its role within
cellular differentiation, however, is uncertain. p53 has
been considered non-essential to development since p53
null mice are viable and succumb to tumors rather than
developmental malformations [8]. The discovery of low
frequency neural tube defects in p53-deficient mice [11] is
an apparent paradox, suggesting the role of p53 in devel-
opment may be more complex than initially believed.
Interpretation of developmental effects in p53-deficient
models at the organismal level are complicated by the
overlapping transcriptional functions of the p53 family
members p63 and p73 [58] which include such vital tar-
gets as p21Waf1/Cip1, Bax and MDM2 and likely other
unknown target genes. In addition, regulation of growth
control and apoptosis can also be carried out through
p53-independent cellular mechanisms which could cir-
cumvent developmental defects in the majority of p53-
deficient mice.
The marked accumulation of p53 protein and serine 15
phosphorylation levels suggesting its activation during
NGF exposure led us to investigate a possible transactiva-
tional role for p53 in neuronal differentiation. Using the
PC12 cell model of NGF-induced neuronal differentia-
tion, we hypothesized that p53 is involved in differentia-
tion through specific transcriptional regulation of target
genes. A contribution of p53 to PC12 cell differentiation
Additional targets with NGF-dependent increase in p53 occupancy, but where p53-dependent transactivation could not be  clearly determined using anti-p53 shRNA expressing cell lines Figure 8
Additional targets with NGF-dependent increase in p53 occupancy, but where p53-dependent transactivation could not be 
clearly determined using anti-p53 shRNA expressing cell lines. Panels A-C show site-specific qPCR ChIP results on left with 
standard deviation, where significance at p ≤ 0.05 is designated by an asterisk (*). GAPDH controls in Figure 7 also apply to 
gene expression analyses in Figure 8. Note the p53-occupied sequence in Panel A lies between genes which were both exam-
ined for changes in expression. Display and analyses are as described in Figure 4 legend.BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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is suggested by the reduction of neurite outgrowth
observed during p53 knockdown studies described here,
which is consistent with previous work showing similar
findings using a temperature-sensitive p53 mutant
[39,40]. However, we demonstrate p53-dependence for
target gene transcription using three PC12 cell lines with
varying levels of shRNA-mediated p53 silencing, further
enabling inference into the transcriptional sensitivity of
each target gene to reduced levels of p53 protein. The 7-
day time point of NGF treatment was selected for further
analysis to explore p53 transcriptional activity at the time
of highest p53 protein accumulation representing a stable
timeframe of p53-DNA occupancy following NGF expo-
sure. As the ChIP-cloning approach utilized here is essen-
tially a snapshot of p53-DNA occupancy following 7 days
of NGF exposure, it is interesting to consider that the pop-
ulation of p53-regulated gene targets may vary over time
following NGF treatment.
Here we describe a number of novel p53-occupied
genomic sites within the NGF-differentiated Rattus nor-
vegicus neuronal PC12 cell line, and further identify corre-
sponding genes regulated by p53 binding to these regions.
The transcriptional targets described here represent entic-
ing mechanisms through which PC12 cellular differentia-
tion may be controlled by activated p53. Particularly
interesting is the regulation of wnt7b  and the tfcp2l4
grainyhead homolog gene. Transcriptional regulation of
Wnt pathway genes by p53 has been described for several
factors, including the negative regulator Dickkopf-1 [59],
the transcription factor Tcf-4 [60] and beta-catenin [61].
Until now, direct DNA binding and transcriptional regu-
lation of Wnt genes themselves has not been previously
reported for p53. Wnt7b functional activity is necessary
for dendritic development and neuronal connectivity in
hippocampal neurons [62], consistent with the general-
ized lack of neurite extension observed in NGF-treated
p53 knockdown PC12 cells in this study. The transcrip-
tional regulation of wnt7b by p53 may be extensible to
other cell types. For example, macrophage-derived wnt7b
has been reported as an apoptotic initiator in vascular
endothelial cells of the developing eye [63], raising the
qRT-PCR expression analyses of p53 targets following geno- toxic exposure Figure 10
qRT-PCR expression analyses of p53 targets following geno-
toxic exposure. A) mRNA expression levels of known p53 
targets comparing naïve, 7-day NGF (50 ng/mL), 6 h 5-fluor-
ouracil (375 µM) and 6 h bleomycin (10 µg/mL) exposure. 
Expression was measured via real time PCR and normalized 
to naïve expression levels using 2-∆∆ct where significance at p 
≤ 0.05 is designated by an asterisk (*). Error bars represent 
standard deviation. B) Same as in Panel A, depicting genes 
whose expression levels were not regulated in the same 
manner between NGF treatment and genotoxic treatment. 
C) Same as in Panel A, depicting genes with comparable regu-
lation between NGF treatment and genotoxic exposure.
WebLogo multiple sequence alignment of p53 binding sites Figure 9
WebLogo multiple sequence alignment of p53 binding sites. 
Individual base letter height indicates level of conservation 
within each binding site position. A) Consensus sequence of 
p53-induced targets shown in Figures 4 and 5. B) Consensus 
sequence of p53-repressed targets shown in Figure 6.BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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possibility of p53 apoptotic control in immune cells
through localized secreted factors.
The transcription factor cp2-like 4 gene, a Rattus norvegicus
grainyhead family homolog, is homologous to the grhl3
mouse and human family members. In Drosophila, the
grainyhead gene product participates in wnt-frizzled sign-
aling in the establishment of wing planar polarity [64]
and in cuticle barrier formation and function [65]. The lat-
ter function is conserved in mammals, where grainyhead
homologs are involved in epidermal stratification and
wound repair [66]. The importance of the grhl3 transcrip-
tion factor during development is underscored in the
grhl3-null mouse, in which neural tube defects are preva-
lent [67,68]. Absence of the p53-tfcp2l4 network in p53-
null mice may represent a potential mechanism through
which a proportion of these mice are born with neural
tube defects. The role of grhl3 in ectodermal differentia-
tion and specification into epidermal tissue and also
within epidermal wound healing is strikingly similar to
the demonstrated involvement of the p53 family member
p63 in these events [69]. Since p63 has an overlapping
transcriptional program with p53 [58], investigation into
joint regulation of tfcp2l4 is warranted as a possible com-
mon juncture of in vivo redundant transcriptional control
in development.
Other transcriptional targets of p53 found in our study
may play roles within the differentiating PC12 cell or
developing organism. The nme1/nm23 gene is a positive
regulator of neuronal differentiation through regulation
of Rb2/p130 expression [70]. The Kctd (potassium chan-
nel tetramerization domain containing) family, of which
FLJ12242 is a member, is involved in the left-right symme-
try of developing zebrafish brain [71]. We found FLJ12242
to be the most highly expressed p53-regulated gene in
NGF-mediated differentiation. Txnl2 is involved in P19
cardiac cell differentiation [72], while BRK promotes ente-
rocyte differentiation [73]. The Sdk2 neuronal adhesion
molecule is involved in synaptic connectivity [74]. Dusp5
is a negative regulator of ERK signaling [75], thus regulat-
ing MAPK signal propagation. The Lect1/Chm1 gene, an
anti-angiogenic factor in differentiating cartilage [76] and
a bone remodeling factor [77], may be involved in bone
development. Furthermore, the additional unannotated
p53-regulated targets described here such as FLJ32743,
LOC366671  and LOC362557  may be important in yet
unknown developmental, differentiation or signaling
processes.
Data from previous studies have reported a number of
p53 regulated genes that do not completely correspond to
expression changes observed in PC12 differentiation. This
observation suggests that p53 transcriptional regulation
in response to diverse stimuli shows similar gene expres-
sion but also some level of stimulus specificity. For exam-
ple, our data show an overlap of p53 occupancy at some
genomic loci irrespective of the p53-activating stimulus
when compared to results from a recent chromatin immu-
noprecipitation/paired-end ditag (ChIP PET) screen for
p53 genomic occupancy in human colorectal cells treated
with 5-fluorouracil, [5] and another study identifying
p53-regulated genes through microarray analysis from
irradiated wild-type and p53-null animals [54]. We con-
firmed the findings of p53 occupancy at the Snk/Plk2 [54],
MDMX, Nck2, Dyrk3, p21Waf1/Cip1, MDM2 and cyclin G1
[5] regulatory regions but we observe p53-dependent
expression changes only in the p21Waf1/Cip1, MDM2 and
cyclin G1 targets with NGF treatment. Regulation of Snk/
Plk2, MDMX, Nck2 and Dyrk3 may not completely depend
upon p53 promoter binding alone but also on availability
of other transcriptional cofactors. Since these targets were
previously identified as p53-regulated, by extension, the
genes we report as shmt1, rnf10, hmmr, trim34, znf609 and
ovary-specific MOB-like protein may also be regulated under
other p53-activating conditions. Along with the NGF-
dependent regulation of p53 gene targets described in our
study as wnt7b, pkcbpb15 and lect, we believe that the p53-
occupied targets shmt1, rnf10, hmmr, trim34, znf609 and
ovary-specific MOB-like protein may provide additional
examples of stimulus-dependent p53 transcriptional tar-
gets. Interestingly, we did not find enrichment of p53-
occupied loci in NGF-differentiated PC12 cells for media-
tors of apoptosis or DNA repair [see Additional file 2]
probably because these recognized functions of p53 are
not involved in NGF differentiation. For instance, we did
not observe DNA repair genes, MLH1 and PMS2, found in
a recent p53-binding genomic study through serial analy-
sis of binding elements (SABE) in p53-expressing Jurkat
cells and verified in cisplatin challenged fibroblasts [78].
In addition, computational approaches combining ChIP,
DNA microarray with p53 sequence binding matrices
have derived genomic maps of candidate p53 binding
sites that reveal p53 regulation of a proapoptotic gene,
BCL-G/BCL2L14 [79], various coding and non-coding
genes [4] and regulation of micro-RNAs [80]. By compar-
ison, we show that NGF-directed p53 transcription in neu-
ronal cells regulated several genes unique to
differentiation and different from transcriptional targets
previously identified in other p53 genome-wide studies.
NGF receptor-mediated induction of p53 activity through
TrkA [39,44] may represent a useful therapeutic avenue
for development of non-genotoxic chemotherapeutics
[29]. While activation of the p53 protein in response to
NGF treatment within PC12 cells has recently been
described [44], it is less clear what particular signaling
proteins are responsible for the marked increase in p53
protein stability and transactivational selectivity. Changes
in p53 activity are related, directly or indirectly, to TrkABMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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activated signaling pathways, such as Ras/MAPK [81].
Activation of the low affinity NGF receptor p75NTR by NGF
results in apoptosis in Schwann cells [82] through the
activity of p53 [83]. TrkA high affinity and p75NTR low
affinity NGF receptors may represent a useful model
through which the divergent 'choices' between cell cycle
arrest/differentiation and apoptosis by p53 protein func-
tion can be studied. Notably, NGF-induced PC12 cell dif-
ferentiation results in little or no detectable apoptosis,
despite markedly increased p53 levels and transcriptional
activity over the extended time course of several days. It is
thus likely that both the inducing agent (i.e. stimulus) and
cell type lend specificity to the p53-controlled transcrip-
tional response observed for other p53-responsive condi-
tions [84]. In addition, the continued transcription of
MDM2 and cyclin G1 described here is in apparent oppo-
sition to elevated p53 protein levels following NGF treat-
ment. MDM2 functions as the major negative regulator of
p53 protein within the cell [85], while cyclin G1 exerts its
negative regulatory role through MDM2 dephosphoryla-
tion and subsequent stabilization [86]. However, contin-
ued stabilization of p53 protein during NGF-induced
differentiation occurs despite the increased MDM2 and
cyclin G1 RNA levels shown here and maintained MDM2
protein levels (data not shown). This suggests the pres-
ence of an intermediate event either inhibiting MDM2
function, or protecting p53 protein from MDM2 function,
in differentiating PC12 cells. The incongruent time frames
of activation for NGF-induced p53 compared to the rela-
tively rapid stabilization via genotoxic agents further sug-
gests the presence of a mechanism distinct from DNA
damage through which p53 stabilization and activation
may occur during NGF-mediated signaling.
The approach used here in the identification of p53-regu-
lated elements in neuronal differentiation represents a
useful strategy amenable to the analyses of DNA binding
by other transcription factors. The recognized roles of
NGF-induced p53 transcriptional targets identified in this
report raise new prospects for a role of p53 in differentia-
tion and development. Further, we provide evidence dem-
onstrating stimulus-specific selectivity by activated p53
protein in transactivation.
Conclusion
Nerve growth factor-mediated activation of p53-depedent
transcription represents an unusual example of receptor-
mediated, non-genotoxic p53 activation. Using a global
chromatin immunoprecipitation cloning technique, we
have identified and validated 14 novel transcriptional tar-
gets of NGF-activated p53 protein during neuronal PC12
differentiation. This study provides evidence of a func-
tional role for p53 in differentiation.
Methods
Cell culture and treatments
PC12 cells (ATCC, Manassas, VA) were propagated in
RPMI 1640 medium (Invitrogen, Carlsbad, CA) supple-
mented with 2 mM L-glutamine, 10% horse serum (Invit-
rogen), 5% fetal bovine serum (Invitrogen) and
appropriate antibiotics in a humidified incubator main-
tained at 37° with 5% CO2. PC12 cells (passage 10–25)
were differentiated on rat tail collagen-coated culture ves-
sels (Sigma, St. Louis, MO) in RPMI 1640 medium con-
taining 1% horse serum, 2 mM L-glutamine and
antibiotics with 50 ng/mL mouse nerve growth factor,
(NGF 2.5S) (Chemicon, Temecula, CA) for indicated time
intervals. Differentiation medium was replaced and fresh
NGF 2.5S was added every third day to differentiating
cells. PC12 cells were incubated with genotoxic agents at
the following concentrations, at the indicated time points:
bleomycin, 10 µg/mL (Sigma) and 5-fluorouracil, 375 µM
(Sigma). Reporter assay was performed by transient trans-
fection of p53TA-luc vector (BD Pharmingen, San Diego,
CA) into naïve PC12 cells plated onto collagen-coated
dishes using Lipofectamine 2000 (Invitrogen). Cells were
treated with NGF the following day and luciferase activity
was quantified using the Luciferase Assay System
(Promega, Madison, WI) at the indicated time intervals on
a Tropix (Bedford, MA) TR717 luminometer. Statistical
analysis of reporter assay data was performed using one-
way ANOVA followed by Tukey's HSD post-hoc test for
significance.
Generation of stable shRNA expressing cells
Stable anti-p53 shRNA expressing PC12 cells were gener-
ated via lentiviral-mediated infection, integration and sta-
ble selection (BlockIt Lentiviral Expression System,
Invitrogen). Hairpin sequences were designed and synthe-
sized (IDT, Coralville, IA) with appropriate overhangs for
cloning into the pENTR/U6 entry vector. The informative
p53-targeting sense hairpin sequences are: p53-2mid – 5'-
GCATACGGATTTCCTTCCACC-3', p53-3low – 5'-ATATC-
CGACTGTGAATCCTCC-3', p53-4mid – 5'-AAAATTAG-
GTGACCCTGTCGC-3'. shRNAs were designed using the
4-base loop sequence CGAA. Hairpin sequences were
cloned into the pENTR/U6 vector and selected clones
were sequence-verified. The U6 promoter-shRNA cassettes
were transferred into the pLenti6-BLOCK-iT-DEST vector.
The resulting destination clones were used to generate len-
tiviral particles by transfection of HEK293FT cells along
with the pLP1, pLP2 and pLP/VSVG plasmids in equal
amounts using FuGene (Roche Diagnostics, Indianapolis,
IN) lipid reagent. Transfection efficiencies were moni-
tored by concomitant tranfection of the pEYFP-C1 vector
(BD Clontech, Mountain View, CA), demonstrating effi-
ciency ≥ 90% in all cases. Lentiviral-laden media was col-
lected 48 hours following transfection, clarified by
centrifugation and used with 4 µg/mL polybrene (Sigma)BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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in transduction of naïve PC12 cells plated on collagen.
Selection using 6 µg/mL blasticidin was initiated and
maintained for 7 days until stable lines were enriched.
Cells were maintained for 14 days before differentiation
and experimentation. Experiments using stable shRNA-
expressing PC12 cells were compared to wild-type PC12
cells of the same original population and passage number
in all cases.
Western blotting
Sample preparation for SDS-PAGE was performed as pre-
viously described [87]. Antibodies used were against nes-
tin (Rat401, Pharmingen), dopamine transporter
(D2442, Sigma), p53 (pAb122, Pharmingen), phospho-
serine 15 p53 (No. 9284, Cell Signaling, Davers, MA) and
actin (MAb1501, Chemicon). Proteins were visualized
using either ECL reagent (GEH Amersham, Piscataway,
NJ) or SuperSignal reagent (Pierce, Rockford, IL).
Chromatin immunoprecipitation assays
ChIP assays were performed similarly to previous reports
[88,89]. Briefly, NGF-differentiated and naïve (dividing)
PC12 cells were crosslinked by 1% formaldehyde with
rocking for 15 minutes before terminating the crosslink-
ing reaction with 125 mM glycine. Cells were washed,
lysed by Dounce homogenization and resupended in a
buffer containing sodium deoxycholate, SDS and Triton
X-100 [88]. Chromatin was sheared to an average length
of 500 bp by sonication on ice and samples were clarified
by centrifugation at 10,000 × g. Sheared, crosslinked chro-
matin complexes were precleared with protein A agarose.
p53-DNA complexes were immunoprecipitated using
anti-full length p53 polyclonal antibody (FL-393, Santa
Cruz Biotech, Santa Cruz, CA) or with control rabbit IgG
(I-5006, Sigma). Immune complexes were captured with
protein A agarose and beads were washed as described
[88,89]. Protein/DNA complexes were eluted and
crosslinks reversed by incubating at 65°C for at least 6
hours. To assay for p53 binding sites in purified ChIP
DNA, target specific primers [See Additional file 1; Table
2] were used to measure amounts of target sequence in
immunoprecipitated samples by qPCR using SYBR Green-
based detection (BioRad, Richmond, CA). Experimental
qPCR values were normalized against values obtained for
25 ng of input DNA using the same primer set. Non-spe-
cific enrichment of chromatin was minimal as determined
by the amplification of enriched ChIP DNA using primers
designed to multiple non-transcribed genomic regions.
Cloning and analysis of enriched ChIP DNA
Cloning of enriched ChIP DNA was performed by using
Genpathway's (San Diego, CA) FactorPath Discovery
approach, as previously described [89]. Enriched ChIP
DNA was incubated with T4 DNA polymerase to generate
blunt ends, ligated to a DNA adapter X consisting of
annealed 25-nt and 11-nt oligonucleotides [90], and PCR
amplified using the 25-nt adapter X oligonucleotide as
primer. A 40–50 bp tag library was generated from the
amplified ChIP DNA by the strategy described in [90].
Amplified ChIP DNA was mixed with "random primer A"
consisting of a fixed sequence A (containing a Bgl II
restriction site) and a randomized 9-nt sequence at the 3'
end. After denaturation of the DNA followed by chilling
of the sample on ice, the annealed random primers were
extended using Klenow DNA polymerase [90]. Extension
products were purified on Sephacryl S-400 HR spin col-
umns (GE Healthcare, Chalfont St. Giles, UK) and mixed
with "random primer B", which differed from "random
primer A" by having a different fixed sequence B (also
containing a Bgl II restriction site). For second strand syn-
thesis, denaturation, incubation with Klenow DNA
polymerase and purification on Sephacryl S-400 HR was
repeated as described above for first strand synthesis. The
resulting DNA was amplified by PCR using primers A and
B, and amplified DNA was electrophoresed on a native
polyacrylamide gel (BioRad). DNA fragments of 80–90 bp
were isolated, re-amplified with primers A and B and sub-
jected to a second round of gel-purification. The DNA was
then digested with restriction endonuclease Bgl II to excise
the 40–50 bp tags representing genomic sequences. After
gel-purification, tags were concatemerized by ligation in
the presence of a limiting amount of adapter C containing
a Bgl II-compatible 4-nt overhang on one end and a blunt-
end on the other end. Ligation products were amplified
using the adapter C sequence as PCR primers, and prod-
ucts containing 10–15 tags were gel-purified, cloned into
the pCR2.1-TOPO vector (Invitrogen) and sequenced. A
detailed diagram [see Additional file 1; Figure 5], summa-
rizes these procedures for cloning and analysis of enriched
ChIP DNA. Individual tag sequences were aligned to
NCBI Rat Genome Build v3.4 using MEGABLAST v2.2.11.
Tags producing low-scoring or multiple alignments were
eliminated from consideration. Clusters were generated
by grouping of tags mapping to within 2 kb of each other.
Alignments were associated with annotated or predicted
genes mapping to within 10 kb of each tag. The presence
of a consensus p53 binding site was determined in each
tag by querying 500 bp of bilateral genomic sequence
flanking each tag using the p53MH algorithm [47]. Func-
tional assessment of genetic elements associated with
individual tags was performed using GoMiner [91] and
grouped into ontological subsets for further analysis and
selection. To confirm candidate p53 binding sites, PCR
primers targeting a region within 200 bp of each selected
alignment or cluster [See Additional file 1; Table 2] were
used to measure the amount of sequence in immunopre-
cipitated sample by qPCR as described above.BMC Genomics 2007, 8:139 http://www.biomedcentral.com/1471-2164/8/139
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Quantitative reverse-transcriptase and real-time 
polymerase chain reactions
PC12 cells were NGF-differentiated as above and har-
vested at indicated intervals. Total RNA was harvested
(Qiagen, Valencia, CA) according to manufacturer's pro-
tocol. RNA concentration was determined using a Nano-
Drop spectrophotometer (BioRad). Equal amounts of
RNA sample were used for SuperScript II first-strand
cDNA synthesis (Invitrogen). RT-PCR was carried out
using 1 µL of cDNA per sample, HotStart master mix
(SuperArray, Frederick, MD) and 0.25 µM each primer
(IDT) in a GeneAmp 9700 PCR instrument (Applied Bio-
systems, Foster City, CA) for the indicated number of
cycles. Equivalent volume of each PCR reaction was run
on 2% TBE agarose gels containing ethidium bromide and
photographed under UV illumination. Each target was
amplified using an appropriate, empirically determined
cycle number allowing gel-based visualization of samples
within the exponential amplification phase of each reac-
tion. Band intensity was measured by integration using
ImageJ software [92] and normalized relative to naïve
expression value.
qRT-PCR expression analysis was performed with cDNA
prepared as above in reactions using the Syber Green qRT-
PCR master mix (ABI) and analyzed by an ABI Model
7900 Prism instrument. All reactions were carried out in
triplicate and measurements analyzed using the relative
quantitation 2-∆∆Ct  method. The housekeeping gene
GAPDH was used as an endogenous control to which
sample measurements were normalized. The ROX passive
reference dye was used to normalize reaction conditions
across sample wells. Naïve PC12 RNA levels for each gene
were used as the reference calibrator to which the NGF-
treated sample RNA levels were compared. Statistical anal-
ysis of qRT-PCR data was carried out using Student's t-test
for significance at p ≤ 0.05 comparing treatment to naïve
gene expression levels.
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